LONP1 and prostate carcinoma: Antibody_82-M1 effectively blocks the ATP-binding site of LONP1, demonstrating high affinity, favorable stability, a high degree of humanization, and excellent drug-like properties, indicating strong potential for clinical translation.<h4>Conclusion</h4>The designed LONP1 inhibitory antibody offers a novel strategy for prostate cancer treatment.